NCT02762591Approved For Marketing不适用
Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient meets one of the following criteria:
- •Patient has participated in a previous study of pimavanserin for Parkinson's disease psychosis (PDP)
- •New ("De novo") patients
- •A clinical diagnosis of Parkinson's disease with a minimum duration of 1 year
- •Female patients must be of non-childbearing potential
- •Psychotic symptoms must have developed after Parkinson's disease diagnosis was established
- •Patient that has received stereotaxic surgery for subthalamic nucleus deep brain stimulation must be at least 6 months post-surgery and the stimulator settings must have been stable for at least 1 month prior to Study Day 1 (Baseline) and must remain stable during the trial
- •The patient or Legally Authorized Representative (LAR) is willing and able to provide consent
- •The patient or LAR is willing and able to adequately communicate in English.
排除标准
- •Patient has a history of significant psychotic disorders prior to or concomitantly with the diagnosis of Parkinson's disease including, but not limited to, schizophrenia or bipolar disorder
- •Patient has had dementia prior to or concurrently with their diagnosis of Parkinson's disease that may be inconsistent with a Parkinson's diagnosis
- •Patient has current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program
- •Patient has had a myocardial infarction in last six months
- •Patient has any surgery planned during the screening, treatment, or follow-up periods
- •Patients will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of psychosis severity, delirium, dementia, cardiovascular condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).
研究者
相似试验
No Longer Available
不适用
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)NCT05086094Biohaven Pharmaceuticals, Inc.
Approved For Marketing
不适用
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNCT04599712Janssen Research & Development, LLC
Approved For Marketing
不适用
Donidalorsen Expanded Access Program for Patients With Hereditary AngioedemaHereditary AngioedemaNCT06415448Ionis Pharmaceuticals, Inc.
Approved For Marketing
不适用
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment OptionsAdvanced Cancers and FGFR Genetic AlterationsNCT03825484Janssen Scientific Affairs, LLC
Approved For Marketing
不适用
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, FamilialFamilial Amyloid PolyneuropathiesAmyloid NeuropathiesAmyloidosis, Hereditary, Transthyretin-RelatedNCT02939820Alnylam Pharmaceuticals